Shares of Gilead Sciences, Inc. (NASDAQ:GILD) ended Wednesday session in green amid volatile trading. The shares closed up +0.03 points or 0.04% at $77.62 with 8.32 million shares getting traded. Post opening the session at $77.94, the shares hit an intraday low of $77.44 and an intraday high of $78.40 and the price vacillated in this range throughout the day. The company has a market cap of $101.41 billion and the numbers of outstanding shares have been calculated to be 1.32 billion shares.
Gilead Sciences, Inc. (GILD) on August 23, 2016 announced that Kelly A. Kramer has been appointed to the company’s Board of Directors and Audit Committee.
Ms. Kramer is currently Executive Vice President and Chief Financial Officer of Cisco Systems, Inc., which designs and sells products, services and solutions to securely connect everyone and everything. She previously served for 20 years in senior finance positions at General Electric, including as Chief Financial Officer of GE Healthcare’s Healthcare Systems Business. She is a member of the board of the Silicon Valley Chapter of City Year, a non-profit organization that provides educational support for at-risk students in poor communities.
“We are very pleased to welcome Kelly Kramer to the Board of Directors of Gilead Sciences,” said John Martin, PhD, Executive Chairman of Gilead’s Board of Directors. “Kelly’s deep financial expertise in the technology and healthcare industries, including mergers and acquisitions, will be valuable as Gilead continues to grow across multiple therapeutic areas and around the world. I look forward to the contributions and insights that she will bring to the Board.”
Shares of Opko Health Inc. (NASDAQ:OPK) ended Wednesday session in green amid volatile trading. The shares closed up +0.15 points or 1.49% at $10.19 with 8.15 million shares getting traded. Post opening the session at $10.02, the shares hit an intraday low of $9.96 and an intraday high of $10.23 and the price vacillated in this range throughout the day. The company has a market cap of $5.69 billion and the numbers of outstanding shares have been calculated to be 550.38 million shares.
Opko Health Inc. (OPK) on September 13, 2016 announced the appointment of Jane Pine Wood, Esq. as Chief Legal and Compliance Officer of its wholly owned subsidiary, BioReference Laboratories, effective October 1, 2016.
Ms. Wood is a nationally respected healthcare attorney who has been practicing law for 29 years. She specializes in laboratory regulatory and compliance matters, and has counseled more than 500 pathology groups and 350 clinical laboratories. For the past 28 years she has been with the multi-state law firm McDonald Hopkins LLC, where she is a member of the firm’s board of directors. Ms. Wood is a frequent speaker at national and state laboratory and pathology meetings, is a contributor to association publications and is regularly quoted in the national press. Ms. Wood graduated from the Vanderbilt University School of Law.
“We are delighted to welcome Jane to the BioReference Laboratories team. She has a distinguished legal career, having counseled a multitude of pathology practices and clinical laboratories across the country; she is considered one of the leading legal experts in the field. Her diverse experience and insight on matters impacting the diagnostics and laboratory industries will be of great value as we continue to deliver high quality diagnostic services to improve patient care,” said Gregory S. Henderson, M.D., Ph.D., President of BioReference Laboratories.